Treatment News

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News

November 25, 2015
CDC Says 1.2 Million Americans Are Likely Candidates for PrEP
The CDC has estimated that 1.2 million Americans are candidates for Truvada as PrEP and should be counseled about the HIV prevention method.
November 24, 2015
Anti-Alcoholism Drug Wakes Cells Latently Infected With HIV
The anti-alcoholism drug Antabuse (disulfiram) prompts cells latently infected with HIV to replicate, a finding that could contribute to a strategy for curing the virus.
Mon Dieu, France Approves PrEP!
France has become the first country outside of the United States to approve use of Truvada as pre-exposure prophylaxis (PrEP) to prevent HIV.
November 23, 2015
No Drop in Hep C Rates Among European Gays With HIV
Hepatitis C acquisition among HIV-positive European gay and bi men has steadily increased during the past 25 years, although trends vary by region, with evidence of a recent leveling-off effect in Western Europe.
November 20, 2015
AIDS-Related Deaths Have Fallen in South Africa
The introduction of antiretroviral treatment in South Africa in the mid-2000s reversed what had been a steadily rising AIDS-related death rate in that hard-hit nation.
Daklinza & Sovaldi Better Treats Those With HIV & HCV
Daklinza (daclatasvir) and Sovaldi (sofosbuvir) more effectively cures hepatitis C among those coinfected with HIV than does Sovaldi and ribavirin.
November 19, 2015
Having the Sex Talk With Teens Encourages Safer Sex
Discussions about safer sex between parents and their adolescent children have a modest but significant effect on safer sex practices among teens.
November 18, 2015
U.S. Uninsured Map Troublingly Similar to HIV Prevalence Map
A New York Times map detailing the varying rates of uninsured people shows striking similarities to the distribution of people living with HIV in the United States.
November 17, 2015
Chlamydia, Gonorrhea and Syphilis Are All On the Rise
The U.S. sexually transmitted infection epidemic is expanding, in some cases at an “alarming rate,” according to the Centers for Disease Control and Prevention (CDC).
Hepatitis C May Transmit Sexually From Rectum Without Blood
Men may acquire hepatitis C virus sexually from the rectums of HIV/HCV-coinfected men even when there is no blood present.
November 16, 2015
Very Low HIV Rate in Study of High-Risk Gays on PrEP
A major American real-world study of PrEP among high-risk men who have sex with men has seen a very low HIV rate despite a high rate of other STIs.
November 13, 2015
FDA OKs Harvoni for Hep C Genotypes 4, 5, 6, People With HIV
The FDA has approved new indications for Gilead’s Harvoni: to treat hepatitis C in those with genotypes 4–6 of the virus and in those coinfected with HIV.
November 12, 2015
‘PrEP Works if You Take It’ for Trans Women Too
Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP) protects transgender women against HIV if they take it consistently.
November 11, 2015
Poor Results for New Syringe Designed to Curb Hep C Spread
A new type of syringe apparently falls short at lowering the risk of hepatitis C virus transmission.
Drug-Resistant Gonorrhea Rising Once More
After dropping dramatically in recent years, rates of drug-resistant gonorrhea rose once again in 2014.
November 10, 2015
Europe Finds No Link Between Two Syndromes and HPV Vaccines
According to the European Medicines Agency, there is no link between any of the versions of the human papillomavirus (HPV) vaccine and two syndromes.
November 09, 2015
Four- and Eight-Week HIV Treatments Show Promise
Long-acting injections of a dual-combination HIV treatment, given every four or eight weeks, suppressed the virus as well as an oral regimen.
November 05, 2015
Infections Lead to Many Cancers Among People With HIV
A considerable proportion of the cancer burden among HIV-positive Americans derives from infections.
FDA OKs Gilead's Genvoya, First HIV Combo Pill With New Tenofovir
The FDA has approved Gilead’s single-tablet antiretroviral regimen Genvoya, the first HIV treatment to include a new version of tenofovir.
November 04, 2015
Starting HIV Treatment Earlier Translates to More Bone Loss
Those who begin HIV treatment soon after diagnosis experience more bone loss than those who defer taking antiretrovirals until HIV disease has progressed.
November 03, 2015
HIV Essentially Doubles Aging’s Effect on Heart Attack Risk
Every decade spent living with HIV is equivalent to an additional 10 years of ordinary aging’s contribution to heart attack risk.
November 02, 2015
Curing Hep C Lowers Risk of Death in Those Coinfected With HIV
People coinfected with HIV and hepatitis C have a much lower risk of death after being cured of hep C.
Statins Slow Liver Disease in People With HIV and HCV
Non-cirrhotic people coinfected with HIV and hepatitis C are much less likely to experience liver disease progression if they are taking a statin.
More Treatment News

Have news about HIV? Send press releases, news tips and other announcements to

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has someone ever disclosed your HIV status without your permission?

Choosing Your Meds

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2015 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.